MedTrace Logo

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

NCT02814968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-04-14

No results posted yet for this study

Summary

The aim of the study is to assess the clinical utility of 18F-fluoro-deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) and Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and prostate-specific antigen (PSA) measurements in response prediction to treatment with Enzalutamide in castration-resistant prostate cancer patients.

The study will assess how these 2 imaging modalities perform compared to traditional serial PSA measurements and bone scan in assessing metastatic tumour load, progressive disease and response to treatment with Enzalutamide in castration-resistant prostate cancer patients.

In addition measurements of serially collected circulating tumour cell (CTC) samples, cell-free tumour DNA and RNA will be performed in order to evaluate their predictive value in terms of response measurement.

Conditions

  • Prostate Cancer Metastatic

Interventions

DRUG

Enzalutamide

DEVICE

18-FDG PET/CT

DEVICE

Whole body MRI

DEVICE

Bone scan

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • The European Uro-Oncology Group

    lead OTHER

Principal Investigators

  • Susanne Osanto, MD PhD · The European Uro-Oncology Group (EUOG)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02814968 on ClinicalTrials.gov